Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.55 | N/A | -157.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.55 | N/A | -157.01% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on long-term goals. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to advance their pipeline despite the losses.
Kymera Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.43% decline in stock price following the announcement. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are aware of the challenges ahead but are committed to their long-term strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Option Care Health, Inc.